Alnylam Pharmaceuticals, Inc. (ALNY) Dividend History

Company News

• Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case

  The U.S. Court of Appeals for the Federal Circuit affirmed a district court's finding of noninfringement in favor of Moderna in its patent battle with Alnylam over mRNA-based COVID-19 vaccine technology. The court ruled that Alnylam's patents were not infringed by Moderna's use of the SM-102 lipid in its Spikevax COVID-19 vaccine.

  Benzinga

  Featured Companies: MRNA
• Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight

  The Huntington's disease treatment market is poised for significant growth, driven by rising prevalence rates, advancements in gene-targeting and disease-modifying therapies, and a robust clinical pipeline addressing critical unmet needs.

  GlobeNewswire Inc.

  Featured Companies: ANNX
• Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?

  Pfizer discontinued development of an experimental weight-management pill, highlighting the risks of drug development. The company also faces upcoming patent expirations for key products and a potential slowdown in FDA approvals due to staffing changes at the agency.

  The Motley Fool

  Featured Companies: BBIO BMY PFE
• Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

  The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeutics.

  Zacks Investment Research

  Featured Companies: CORT FBT IBB UTHR XBI
• Leerink Partners upgrades Ionis stock on key asset commercialization - Investing.com

  Leerink Partners upgraded Ionis Pharmaceuticals' stock from Market Perform to Outperform, citing the company's focus on wholly-owned assets like olezarsen and donidalorsen, which are nearing commercialization.

  Investing.com

  Featured Companies: IONS RARE